[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cervical-cancers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cervical-cancers":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,42,69,98,140,182,207,234,259,280,307,334,418,439,462,487,516,540,572,597],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100594670","phase-2-phase-ii-trial-comparison-of-3-vs-4-fractions-brachy-fit-100594670",false,"NCT07022470","Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT).","Brachytherapy Fractionation Individualized by Treatment Feasibility in Cervical Cancer: Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT).","Inclusion Criteria:\n\n* Histologically documented malignancy of the cervix and planned to receive brachytherapy as part of definitive treatment.\n* ECOG performance status of 0-2\n* Age ≥ 18 years old.\n* Ability to understand and the willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Contraindication to receiving radiotherapy as determined by treating radiation oncologist.\n* Contraindication to receiving MRI.\n* Prior radiation to the pelvis \\> 3 months ago\n* Age \\\u003C 18 years old.\n* Pregnant or breast-feeding","ALL","18 Years",{"count":19,"type":20},41,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a prospective non-randomized clinical trial to evaluate the feasibility of 3 fraction versus a standard 4 fraction high dose rate brachytherapy regimen in patients with locally advanced cervical cancer.",[26],"Cervical Cancers",[28],"high dose rate brachytherapy","RECRUITING","2026-06-10",{"date":32,"type":33},"2026-06-12","ACTUAL",{"date":35,"type":33},"2025-06-03",{"date":37,"type":20},"2028-06",{"name":39,"class":40},"Stanford University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":41},"100579545","unidos-contra-el-vph-100579545","NCT06825689","Unidos Contra el VPH","Unidos Contra el VPH: Screening Preference and Uptake of HPV Self-sampling Among Latinxs Along the US-Mexico Border","Unidos","Inclusion Criteria:\n\n* Individuals with a cervix who are 30-65 years and have not undergone a Pap test in at least three years.\n\nExclusion Criteria:\n\n* Having had a hysterectomy or a personal history of cervical cancer.",true,"FEMALE","30 Years","65 Years",{"count":55,"type":20},735,[57],"NA","The purpose of the Unidos Contra el VPH study is to help find options to screen, or check, for cervical cancer that individuals can do at home to help prevent and detect cervical cancer early. Usually, people get screened for cervical cancer with a Pap smear and human papillomavirus (HPV) test by a health care provider. This is not always easy for individuals who are not able to get to a clinic or feel uncomfortable having the procedure done. That is why we want to find other ways that may be easier and more comfortable for people to be screened for cervical cancer.\n\nThe two main questions the study aims to answer are:\n\n1. How do the following three cervical cancer screening methods compare for improving screening completion rates?\n\n   o In-home HPV self-sampling with a vaginal swab\n   * In-home HPV self-sampling with urine testing\n   * In-clinic traditional Pap smear with HPV test\n2. What are participant beliefs and preferences regarding these three screening methods?\n\n   Participants in the study will be randomly assigned to one of three groups. This means each person has an equal chance of being placed in any group. They will also complete two surveys as part of the study. The three screening method groups are described below:\n\n   Group 1: Urine Self-Sampling\n   * Participants in this group will receive a kit with a urine sample cup to use at home, instructions explaining how to take the sample and a pre-paid mailing box to mail the urine sample to the lab.\n\n   Group 2: Vaginal Swab Self-Sampling o Participants in this group will receive a kit with a vaginal swab and collection tube to use at home, instructions explaining how to take the sample and a pre-paid mailing box to mail the sample to the lab.\n\n   Group 3: In-Clinic Screening\n   * An in-clinic co-testing appointment is scheduled for a Pap smear and HPV test done together at Project Vida Health Center.\n\n   By comparing these approaches, this study aims to improve access to cervical cancer screening and provide better options for those who face barriers to clinic-based screening.",[60,26],"Human Papilloma Virus (HPV)","2026-06-08",{"date":30,"type":33},{"date":64,"type":33},"2025-01-28",{"date":66,"type":20},"2029-02",{"name":68,"class":40},"University of Texas at Austin",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":80,"conditions":81,"keywords":85,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":97},"100577541","phase-1-study-of-xnw28012-in-subjects-with-advanced-solid-tumors-who-failed-standard-treatments-100577541","NCT06799637","Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments","A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Efficacy of XNW28012 in Subjects With Advanced Solid Tumors","Inclusion Criteria:\n\n1. For the dose escalation part: subjects with histologically or cytologically confirmed advanced and\u002For metastatic solid tumors who have failed the established standard anti-cancer therapies for a given tumor type or have been intolerant to such therapies.\n2. For the dose expansion part: subjects must have a histological or cytological diagnosis of progressive, locally advanced, and\u002For metastatic ovarian cancer, cervical cancer, pancreatic cancer, or colorectal cancer (CRC) who have failed the following anti-cancer therapies: Ovarian cancer, Cervical cancer, Pancreatic cancer, Colorectal cancer.\n3. Age ≥ 18 years old at the time of consent.\n4. Subjects must have at least 1 measurable lesion as defined per RECIST version 1.1 (for dose expansion part only).\n5. Subjects must have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale. ECOG status of 2 can be allowed if it is a result of disease progression and warrants discussion with the medical monitor.\n6. Subjects must have adequate organ function within 7 days prior to the first study drug administration, as indicated by the flaboratory values:\n7. Life expectancy of at least 12 weeks.\n8. Females of childbearing potential must have a negative pregnancy test within 7 days prior to the first dose of study drug. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n9. Non-sterile subjects must be willing to use a highly effective contraception (e.g., IUD, pill, or condom) for the duration of the study and for 6 months after the last dose of study drug unless their partner is sterilized.\n10. Subjects are able to provide written informed consent, understand and are willing to comply with the requirements of the study.\n\nExclusion Criteria:\n\n1. A history of severe infusion reactions to other monoclonal antibodies\u002Fantibody drug conjugates (ADCs) or allergic reactions to any components of XNW28012.\n2. Any anti-tumor therapy within 28 days prior to the first dose, including but not limited to: small molecules, immunotherapy, chemotherapy, monoclonal antibodies, or any other experimental drugs.\n3. Any active malignancy, with the exception of the specific types of cancers under investigation in this study and any locally recurring cancer that has been treated curatively .\n4. Have received a live vaccine within 4 weeks prior to the first dose of study drug. Note: Seasonal vaccines for influenza are generally inactivated vaccines and are allowed; however, intranasal influenza vaccines will not be allowed if they are attenuated live vaccines.\n5. Have received granulocyte colony stimulating factor (G-CSF) or granulocyte \u002F macrophage colony stimulating factor support within 1 week before screening, or pegylated G-CSF within 2 weeks before screening.\n6. Subjects with toxicities (as a result of prior anti-cancer therapy) which have not improved to CTCAE grade ≤1 or stabilized, except those AEs not considered as a likely safety risk (e.g., alopecia).\n7. Any history of intracerebral arteriovenous malformation, cerebral aneurysm, or stroke (transient ischemic attack) ≤ 3 months prior to screening is allowed if stable.\n8. Any of the hematological risk factors:\n9. Subjects who are unwilling or unable to provide tumor tissue samples that meet the requirements for tissue factor (TF) expression testing.\n\n11\\. Clinically significant cardiovascular\u002Fcerebrovascular conditions. 12. Active ocular surface disease at screening, or subjects with any prior episode of cicatricial conjunctivitis.\n\n13\\. Any history of Toxic Epidermal Necrolysis (TEN) or Steven Johnson Syndrome. 14. Subjects who have undergone major surgery within 28 days prior to the first dose of study drug, except if the procedure is minimally invasive (for example, introduction of peripherally inserted central catheter \\[PICC\\] line).\n\nand so on.",{"count":77,"type":20},350,[79,23],"PHASE1","This is an open-label, dose escalation, multicenter, phase 1, first-in-human study of XNW28012 in subjects with advanced solid tumors who have failed current standard anti-tumor therapies or are intolerant to such therapies. The study consists of two parts: a dose escalation part and a dose expansion part.",[82,83,84,26],"Advanced Solid Tumors","Pancreatic Carcinoma","Ovarian Cancer",[86],"XNW28012","2026-04-14",{"date":89,"type":33},"2026-04-15",{"date":91,"type":33},"2023-12-01",{"date":93,"type":20},"2026-12-31",{"name":95,"class":96},"Evopoint Biosciences Inc.","INDUSTRY",24,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":107,"briefSummary":108,"conditions":109,"keywords":124,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":139},"100586075","phase-1-idov-immune-for-advanced-solid-tumors-100586075","NCT06910657","IDOV-Immune for Advanced Solid Tumors","A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors","Key Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically or cytologically confirmed advanced solid tumors that have progressed despite standard therapy, or for which no standard therapy exists.\n* ECOG performance status ≤ 1.\n* Measurable disease per RECIST v1.1.\n* Adequate organ and bone marrow function.\n* At least 28 days since major surgery, prior immunotherapy, or radiotherapy (with exceptions for minor procedures).\n* Negative pregnancy test for women of childbearing potential.\n* Agreement to use effective contraception during treatment and for 3 months after.\n* Ability to provide informed consent and comply with study requirements.\n\nKey Exclusion Criteria:\n\n* Prior treatment with an oncolytic virus.\n* Active or recent vaccinia virus infection or smallpox\u002Fmonkeypox vaccination within 10 years.\n* Active uncontrolled infection requiring systemic treatment.\n* History of hepatitis B, hepatitis C, or HIV (unless meeting protocol-specific criteria).\n* Unresolved ≥ Grade 2 toxicities from prior therapies (except hair loss or stable chronic conditions).\n* Active or symptomatic autoimmune disease requiring systemic therapy.\n* Active or untreated CNS metastases (unless stable per protocol).\n* Significant cardiac disease (e.g., NYHA Class III\u002FIV heart failure).\n* Interstitial lung disease or prior pneumonitis requiring steroids.\n* Conditions requiring chronic immunosuppressive therapy.\n* Severe skin disorders or history of pancreatitis.\n* Bleeding disorders or history of recent serious thromboembolic events.\n* Any medical or psychiatric condition that could interfere with study participation.",{"count":106,"type":20},78,[79],"This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor.\n\nThe purpose of this study is to determine the safety of IDOV-Immune, how well it is tolerated, and to identify the highest dose that can be safely given. Researchers will also study how the drug behaves in the body, how the immune system responds to it, and whether it shows any signs of shrinking tumors.\n\nParticipants will receive a single intravenous (IV) infusion of IDOV-Immune and will be closely monitored for side effects and any changes in their cancer.\n\nThis study is being conducted at multiple sites in the United States and Australia.",[110,111,112,84,113,114,115,116,117,118,119,120,121,26,122,123],"Colorectal Cancer","Pancreatic Cancer","Melanoma","Gastric Cancer","Esophageal Cancer","Hepatocellular Carcinoma","Renal Cell Carcinoma","Breast Cancer","Sarcoma","Bladder Cancer","Lung Cancer","Prostate Cancer","Head and Neck Cancers","Adrenal Gland Tumors",[125,82,126,127,128,129],"Oncolytic Virus Therapy","Metastatic Cancer","Refractory Cancer","Immunotherapy","Vaccinia Virus","2026-02-27",{"date":132,"type":33},"2026-03-02",{"date":134,"type":33},"2025-08-25",{"date":136,"type":20},"2027-05-31",{"name":138,"class":96},"ViroMissile, Inc.",6,{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":21,"phases":151,"briefSummary":152,"conditions":153,"keywords":157,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":180,"locationsCount":41},"100578795","validation-of-a-lab-free-low-cost-screening-test-for-prevention-of-cervical-cancer-100578795","NCT06815939","Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical Cancer","Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical Cancer: Automated Visual Evaluation","OPTICS","Inclusion Criteria:\n\n* Women between 30 and 59 years of age\n\nExclusion Criteria:\n\n* Pregnancy at the time of colposcopy\u002Fbiopsy\n* Hysterectomy with surgically absent cervix\n* HPV test in the last 5 years independently of negative or positive result\n* Previous cervical cancer diagnosis or treatment in the last 5 years\n* Lack of willingness or capacity to provide informed consent","59 Years",{"count":150,"type":20},10000,[57],"The purpose of this study is to validate Automated Visual Evaluation (AVE), specifically the CINFinder version developed by DL Analytics, a point-of-care screening and triage diagnostic tool for cervical cancer based on the assessment of digital images through artificial intelligence. Several teams around the world have developed versions of AVE as a triage technology but none as a screening tool.",[154,155,156,26],"Human Papillomavirus (HPV)","Cervical Intraepithelial Neoplasia","Uterine Cervical Neoplasms",[158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,156],"Human Papillomavirus","Cervical Cancer","Screening","Neoplasms","Precancerous Conditions","Uterine Diseases","Uterine Cervical Diseases","Genital Diseases, Female","Female Urogenital Diseases and Pregnancy Complications","Urogenital Diseases","Genital Diseases","Uterine Neoplasms","Genital Neoplasms, Female","Urogenital Neoplasms","Neoplasms by Site","Uterine Cervical Dysplasia","2026-01-27",{"date":176,"type":33},"2026-01-29",{"date":178,"type":33},"2025-02-12",{"date":93,"type":20},{"name":181,"class":96},"DL Analytics",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":189,"targetDuration":4,"studyType":21,"phases":191,"briefSummary":192,"conditions":193,"keywords":194,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":205,"locationsCount":41},"100572004","phase-2-serplulimab-with-chemoradiotherapy-for-postoperative-cervical-cancer-with-risk-factors-100572004","NCT06727617","Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors","Serplulimab Plus Chemoradiotherapy vs Chemoradiotherapy as Adjuvant Treatment for Postoperative Cervical Cancer Patients With Multiple Risk Factors: A Randomized, Open-Label, Phase II Clinical Trial","Inclusion Criteria:\n\n* Voluntarily participate in the clinical study: Fully understand and be informed about the study, and sign the informed consent form (ICF); willing to comply with and capable of completing all trial procedures.\n* Female aged ≥18 years and ≤65 years at the time of signing the ICF.\n* ECOG PS score of 0 or 1.\n* Positive PD-L1 status (CPS ≥1).\n* Diagnosed with cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.\n* FIGO (International Federation of Gynecology and Obstetrics) stage of IB1, IB2, IIA1, or IIA2, and patients judged by the investigator to benefit from radical surgery and\u002For adjuvant therapy.\n* Have undergone radical hysterectomy (Piver classification) and pelvic lymphadenectomy of type II or III.\n* Postoperative pathological examination confirms at least two adverse factors, which may include: Lymph node metastasis; Positive parametrial or positive resection margins; Lymphovascular space invasion; Deep stromal invasion;\n* Patients must meet the following hematological, renal, and liver function criteria: Absolute neutrophil count of at least 1.5 × 10⁹\u002FL; Platelet count of at least 100 × 10⁹\u002FL; Total bilirubin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels not exceeding 1.5 times the upper limit of normal; Creatinine levels not exceeding the upper limit of normal.\n* Female participants must have a negative serum pregnancy test within 14 days prior to treatment and agree to use effective contraception during the treatment period and for 6 months afterward; breastfeeding is prohibited during treatment.\n* Willing and able to comply with the trial and follow-up procedures.\n\nExclusion Criteria:\n\n* Patients with unresectable residual tumors.\n* Histologically confirmed diagnosis of cervical small cell carcinoma (neuroendocrine) or mucinous adenocarcinoma.\n* Patients who have previously received pelvic radiotherapy.\n* History of other untreated malignant tumors within the past 5 years, except for cured basal cell carcinoma of the skin or carcinoma in situ.\n* Presence of any active or known autoimmune disease.\n* History of inflammatory\u002Fautoimmune diseases requiring steroid treatment, or currently suffering from inflammatory\u002Fautoimmune diseases that require steroid treatment.\n* Diseases requiring systemic treatment with corticosteroids or other immunosuppressive agents within 14 days prior to randomization.\n* History of thromboembolic events (venous or arterial) occurring within 6 months prior to enrollment.\n* Poorly controlled clinical symptoms or conditions related to heart disease.",{"count":190,"type":20},134,[23],"A Phase II Study of Serplulimab Plus Chemoradiotherapy as Adjuvant Treatment for Postoperative Cervical Cancer with Multiple Risk Factors",[26],[195,196,197,198],"cervical cancer","high risk","immunotherapy","radiotherapy","2026-01-04",{"date":201,"type":33},"2026-01-06",{"date":203,"type":33},"2024-11-19",{"date":93,"type":20},{"name":206,"class":40},"Tianjin Medical University Cancer Institute and Hospital",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":21,"phases":216,"briefSummary":217,"conditions":218,"keywords":219,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":41},"100542921","the-effects-of-immunonutrition-therapy-on-locally-advanced-cervical-cancer-patients-100542921","NCT06349148","The Effects of Immunonutrition Therapy on Locally Advanced Cervical Cancer Patients","The Effects of Immunonutrition Therapy on the Nutritional Status, Immune Function, and Quality of Life of Locally Advanced Cervical Cancer Patients With Malnutrition: an Open-label Randomized Controlled Study","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Pathological histological diagnosis confirmed as cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma;\n* Confirmed as Locally Advanced Cervical Cancer (LACC) based on gynecological examination and imaging assessment;\n* Undergoing CCRT\u002FRT treatment;\n* Patients are conscious, able to communicate without barriers, and able to answer questions.\n* diagnosed with malnutrition according to the GLIM criteria;\n\nExclusion Criteria:\n\n* Patients who received neoadjuvant chemotherapy or immunotherapy before treatment;\n* Patients with concomitant other malignant tumors or a history of malignant tumors;\n* Patients with special pathological types of tumors such as cervical small cell carcinoma or neuroendocrine tumors;\n* Patients staged as Ⅳb according to the International Federation of Gynecology and Obstetrics(FIGO) 2018 staging system;\n* Patients with other severe chronic debilitating diseases, such as severe heart failure (New York Heart Association Class II-IV), severe liver damage (alanine aminotransferase ≥ 3 times the upper limit of normal), severe renal insufficiency (GFR \\\u003C 30 ml\u002Fmin\\*1.73 m²), etc.;\n* Eastern Cooperative Oncology Group(ECOG) performance status ≥ 2;\n* Presence of other contraindications to CCRT\u002FRT.",{"count":215,"type":20},50,[57],"The goal of this open-label randomized control trial is to study the effect of immunonutrition in locally advanced cervical cancer (LACC) with standard concurrent chemoradiotherapy. LACC patients undergoing radical synchronous chemoradiotherapy will be randomized into the experimental group receiving enteral immunonutrition therapy and the control group receiving standard enteral nutrition support.The main purpose it aims to answer are:1）Can immunonutrition therapy improve patients' dose-limiting toxicity(DLT) and DLT-free survival? 2）Can immunonutrition therapy improve patients' nutritional status and quality of life?",[26],[220,221,222,223,224],"Cervical cancer","Immunonutrition","Concurrent chemoradiotherapy","GLIM","Sarcopenia","2025-12-04",{"date":227,"type":33},"2025-12-05",{"date":229,"type":33},"2024-01-01",{"date":231,"type":20},"2026-12",{"name":233,"class":40},"SHUANG ZHENG JIA, PhD",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":50,"sex":51,"minAge":242,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":21,"phases":245,"briefSummary":246,"conditions":247,"keywords":248,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":41},"100567541","use-misoprostol-to-optimize-prevention-of-cervical-cancer-100567541","NCT06669533","Use Misoprostol to Optimize Prevention of Cervical Cancer","Misoprostol to Optimizing Prevention of Cancer of the Cervix: A Double-Blind Randomized Controlled Trial","MISOPCx","Inclusion Criteria:\n\n* Diagnosis of Type 3 TZ confirmed on exam prior to randomization\n* Age 25 years or older\n\nExclusion Criteria:\n\n* With Type 1 or 2 TZ prior to randomization\n* Currently pregnant\n* History of hysterectomy\n* Any cancerous lesions\n* Active cervicitis","25 Years",{"count":244,"type":20},420,[57],"This is a double-blind randomized controlled trial of 420 non-pregnant women undergoing cancer screening by visual inspection with acetic acid (VIA) who have Type 3 transformation zone (TZ) and randomized to receive either Misoprostol or placebo.",[26],[249],"cervical cancers","2025-09-29",{"date":252,"type":33},"2025-10-01",{"date":254,"type":33},"2025-02-25",{"date":256,"type":20},"2027-11-04",{"name":258,"class":40},"University of Alabama at Birmingham",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":266,"enrollmentInfo":267,"targetDuration":4,"studyType":21,"phases":268,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":41},"100602955","phase-2-ivonescimab-combined-with-paclitaxel-and-cisplatin-as-neoadjuvant-therapy-followed-by-type-a-hysterectomy-in-stage-ib2-and-iia1-cervical-cancer-100602955","NCT07130240","Ivonescimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Type A Hysterectomy in Stage IB2 and IIA1 Cervical Cancer","Ivonescimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Type A Hysterectomy in Stage IB2 and IIA1 Cervical Cancer: A Phase II Trial","Inclusion Criteria:\n\n(1)Patients with FIGO 2018 stages IB2, IIA1 (2\\\u003C lesion ≤4 cm, confirmed by MRI); (2) Histologically confirmed cervical squamous cell carcinoma, cervical adenocarcinoma, or cervical adenosquamous carcinoma; (3)18-75 years old. (4) ECOG performance status score: 0-1. (5) No prior therapy received by the participant. (6)Expected survival period ≥6 months. (7) Women of childbearing potential must agree to use contraception (e.g., intrauterine device, oral contraceptives, or condoms) during the study and for 6 months after the study ends. A negative serum or urine pregnancy test within 7 days before study enrollment is required, and the patient must not be breastfeeding.\n\n(8) Adequate organ function as defined by the protocol, with test samples collected within 7 days before the start of study treatment.\n\n(9) Participants voluntarily join the study, sign the informed consent form, demonstrate good compliance, and cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Histological subtypes or disease stages other than those permitted in inclusion criteria (1) and (2).\n2. Severe hypersensitivity (≥ Grade 3) to cisplatin, paclitaxel, Ivonescimab , and\u002For any of their excipients.\n3. Participation in another clinical trial within 4 weeks prior to enrollment.\n4. Administration of inactivated vaccines within 30 days before the first study treatment or planned vaccination during the study period.\n5. Treatment with systemic immunostimulants, colony-stimulating factors, interferons, interleukins, or combination vaccines within 6 weeks or 5 half-lives (whichever is shorter) before the first dose.\n6. Diagnosis of immunodeficiency or chronic systemic steroid therapy (exceeding 10 mg prednisone equivalent per day) or any other form of immunosuppressive therapy within 7 days before the first dose.\n7. Active autoimmune disease requiring systemic treatment (e.g., disease-modifying drugs, corticosteroids, or immunosuppressive drugs) within the past 2 years.\n8. History of (non-infectious) pneumonitis requiring steroid treatment or current (non-infectious) pneumonitis.\n9. Active infection requiring systemic treatment.\n10. Known history of HIV infection.\n11. Known history of hepatitis B (defined as HBsAg reactivity) or active hepatitis C virus infection (defined as detectable HCV RNA \\[qualitative\\]).\n12. Known history of active tuberculosis (TB; Mycobacterium tuberculosis).\n13. Prior allogeneic tissue\u002Fsolid organ transplantation.\n14. Central nervous system metastases, such as brain metastases.\n15. Uncontrolled pleural or peritoneal effusion.\n16. Impaired mobility due to pathological fractures caused by bone metastases.\n17. Insufficient bone marrow function (without transfusion within 14 days): a) Absolute neutrophil count (ANC) \\\u003C1.5×10⁹\u002FL;b) Platelets \\\u003C100×10⁹\u002FL; c) Hemoglobin \\\u003C9 g\u002FdL.\n18. Liver abnormalities: a) ALT, AST, or ALP \\>2.5× upper limit of normal (ULN) without liver metastasis or \\>5×ULN with liver metastasis; b) Total bilirubin \\>1.5×ULN (\\>3×ULN in patients with Gilbert's syndrome); c) Decompensated cirrhosis (Child-Pugh class B or C); d) HBsAg-positive with HBV DNA ≥2000 IU\u002FmL (patients with HBsAg-positive and HBV DNA \\\u003C2000 IU\u002FmL must receive at least 2 weeks of anti-HBV therapy before the first dose); e) HCV antibody-positive with detectable HCV RNA.\n19. Kidney abnormalities: a) Serum creatinine \\>1.5×ULN or estimated creatinine clearance \\\u003C60 mL\u002Fmin using the Cockcroft-Gault formula; b) Urinalysis showing protein ≥++ and confirmed 24-hour urine protein \\>1.0 g; c) Renal failure requiring hemodialysis or peritoneal dialysis; d) History of nephrotic syndrome.\n20. Bleeding risk: a) Coagulation abnormalities: Activated partial hromboplastin time (APTT) or thrombin time (TT) \\>1.5×ULN, or international normalized ratio (INR) \\>1.5 (\\>2.5 for patients requiring anticoagulation therapy); b) History of bleeding (e.g., hemoptysis), coagulation disorders, or current use of warfarin, aspirin, low-molecular-weight heparin, or other antiplatelet agents (except for aspirin ≤100 mg\u002Fd for prophylaxis); c) Any signs or history of bleeding diathesis, regardless of severity; d) Active gastrointestinal bleeding, evidenced by hematemesis, hematochezia, or melena within the past 3 months, without resolution confirmed by endoscopy or colonoscopy; e) Any CTCAE ≥ Grade 3 bleeding or hemorrhagic event within 4 weeks before the first dose.\n21. Cardiovascular and cerebrovascular abnormalities: a) Any of the following within 12 months before the first dose: ≥ Grade 2 myocardial ischemia, yocardial infarction, arrhythmias, ≥ Grade 3 cardiac insufficiency, uncontrolled angina, coronary\u002Fperipheral artery bypass graft surgery, symptomatic congestive heart failure, cerebrovascular accident, or transient ischemic attack; b) Deep vein thrombosis or pulmonary embolism within 6 months before the first dose; c) Left ventricular ejection fraction (LVEF) \\\u003C50% assessed by Doppler ultrasound; d) Average QTc interval corrected by Fridericia's formula (QTcF) (based on at least 3 consecutive ECG readings): ≥470 ms for females; e) Uncontrolled hypertension (at least 2 measurements showing systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg).\n22. Other factors judged by the investigator as potentially affecting study results or leading to premature termination, such as alcoholism, drug abuse, other severe diseases (including mental illness) requiring concurrent treatment, significant laboratory abnormalities, or family\u002Fsocial factors that may compromise patient safety.","75 Years",{"count":5,"type":20},[23],"Cervical cancer ranks fourth globally in both incidence and mortality rates, making early diagnosis and treatment of great significance. For early-stage cervical cancer, surgery remains the primary treatment approach. According to the latest NCCN guidelines, patients with Stage IA2 or IB1 cervical cancer confirmed by cone biopsy who meet Concerv or SHAPE criteria no longer require type C\u002FB hysterectomy. Instead, they may undergo type A hysterectomy with reduced surgical margins. However, patients with Stage IB2 or IIA1 tumors measuring 2-4 cm still require radical hysterectomy (type C). Radical hysterectomy carries high risks of postoperative complications and significantly impairs quality of life, including major vascular injury, urinary tract damage and dysfunction, lymphatic complications, and sexual dysfunction. Therefore, there is an imperative need to explore alternative or refined treatment approaches for Stage IB2\u002FIIA1 cervical cancer that ensure survival outcomes while reducing surgical morbidity and improving quality of life.\n\nNeoadjuvant therapy followed by scale-reduced surgery may represent a feasible strategy. Both immune escape and angiogenesis are core drivers of tumorigenesis and progression. Combined immunotherapy and anti-angiogenic therapy have demonstrated favorable antitumor efficacy and manageable safety profiles across multiple tumor types. Ivonescimab is a novel humanized tetrameric IgG-scFv bispecific antibody targeting PD-1 and VEGF. Mechanistically, PD-1 blockade reverses T-cell suppression while VEGF inhibition curbs neovascularization, yielding synergistic therapeutic enhancement. This agent has shown promising efficacy and safety in advanced non-small cell lung cancer, hepatocellular carcinoma, and recurrent glioblastoma, though clinical data in cervical cancer remain absent. Therefore, this prospective exploratory study aims to evaluate the efficacy and safety of neoadjuvant Ivonescimab combined with paclitaxel and cisplatin followed by type A hysterectomy for stage IB2\u002FIIA1 cervical cancer. The findings may provide novel insights for optimizing treatment paradigms-ensuring survival outcomes while preserving quality of life.",[26],"2025-08-12",{"date":273,"type":33},"2025-08-19",{"date":275,"type":20},"2025-08-15",{"date":277,"type":20},"2030-08-31",{"name":279,"class":40},"Obstetrics & Gynecology Hospital of Fudan University",{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":21,"phases":290,"briefSummary":291,"conditions":292,"keywords":4,"overallStatus":297,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":4},"100600138","emergence-of-bacterial-resistance-to-antibiotics-in-the-digestive-microbiota-of-patients-treated-with-anticancer-drugs-100600138","NCT07093593","Emergence of Bacterial Resistance to Antibiotics in the Digestive Microbiota of Patients Treated With Anticancer Drugs","Emergence of Bacterial Resistance to Antibiotics in the Digestive Microbiota of Patients Treated With Anticancer Drugs (Clinical Component of the RAMA Project)","RAMA","Inclusion Criteria:\n\n* Men and women over 18\n* Chemotherapy-naive patients.\n* Patients due to start chemotherapy\u002Fradio chemotherapy who meet the criteria of the cohorts listed below :\n\n  1. Squamous cell carcinoma of the upper aerodigestive tract (Non-metastatic, locally advanced, operable or not; Patients receiving concomitant radiochemotherapy using a platinum salt (cisplatin, carboplatin))\n  2. Cervical and endometrial cancer (ocally advanced, Non-metastatic; Patients receiving concomitant radiochemotherapy using a platinum salt (cisplatin, carboplatin))\n  3. Gynecological cancer (advanced stage ; Patient to receive platinum salt + paclitaxel chemotherapy)\n  4. Mammary carcinoma (localised; Patient to receive adjuvant or neoadjuvant chemotherapy with epirubicin and cyclophosphamide without other associated treatment (targeted therapy \u002F immunotherapy))\n  5. Urothelial carcinoma (all stage ; Patient to receive neoadjuvant or adjuvant chemotherapy with platinum salt and gemcitabine)\n  6. Pancreatic adenocarcinoma (localised or metastatic ; Patients to be treated with gemcitamine alone or in combination with nab-paclitaxel)\n* OMS ≤ 2\n* Affiliation with a French social security scheme or beneficiary of such a scheme.\n* Signed informed consent indicating that the patient has understood the purpose and procedures of the study and agrees to participate in the study and to abide by the study requirements and restrictions\n\nExclusion Criteria:\n\n* Patients unable to collect \u002F send stools for medical, geographical, social or psychological reasons.\n* Patients who have already received chemotherapy\u002Fradiochemotherapy.\n* Use of anti-infectives for systemic use within 6 months prior to the first sampling, or any other concomitant disease\u002Fcondition that may influence stool analysis.\n* Pregnant women and nursing mothers.\n* Persons deprived of their liberty by judicial or administrative decision; persons under compulsory psychiatric care; persons admitted to a health or social institution for purposes other than research.\n* Adults subject to a legal protection measure - safeguard of justice, guardianship or curatorship - or unable to express their consent.",{"count":289,"type":20},260,[57],"Solid cancers are frequently treated with chemotherapies that target the DNA of cancer cells. It has recently come to light that bacteria are also the target of chemotherapies used in oncology. The results of current studies demonstrate the close link between the composition of the microbiota, the immune system, toxicity and the efficacy or otherwise of anti-cancer treatments.\n\nIn this context, the study will measure the influence of treatment with anticancer molecules known to activate the bacterial SOS response on the emergence of antibiotic-resistant commensal bacteria in the gut microbiota of cancer patients. Furthermore, this study will investigate the existence of a close link between changes in the intestinal microbiota determined by the induction or non-induction of the SOS response, bacterial translocation, the integrity of the intestinal barrier and the antitumor immune response.\n\nThe RAMA trial plans to collect stool and blood samples from two different cohorts of patients:\n\n* Unexposed cohort: patients receiving anti-cancer treatment that does not induce bacterial SOS response.\n* Exposed cohort: patients receiving anti-cancer treatment inducing the bacterial SOS response.\n\nPatients' stools will be collected within 7 days of their first chemotherapy treatment and within 7 days of the 3rd chemotherapy cycle. Two blood samples will be taken at the same time as the stool samples.\n\nThe results obtained from this prospective clinical research will then be investigated in two experimental laboratory models.\n\nThe aim is to demonstrate that cytotoxic anticancer drugs promote the emergence of antibiotic-resistant commensal bacteria, by means of this large-scale study comprising a clinical component, which is the subject of the research presented in this protocol, combined with laboratory research components.",[26,293,294,295,296],"Endometrial Cancer","Gynecological Cancers","Pancreatic Adenocarcinoma","Upper Aerodigestive Tract Carcinoma","NOT_YET_RECRUITING","2025-07-22",{"date":300,"type":33},"2025-07-30",{"date":302,"type":20},"2025-09-01",{"date":304,"type":20},"2032-09-01",{"name":306,"class":40},"Centre Georges Francois Leclerc",{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":21,"phases":316,"briefSummary":317,"conditions":318,"keywords":320,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":41},"100582756","minimally-invasive-pelvic-exenteration-in-vaginal-or-cervical-cancer-recurrence-100582756","NCT06867445","Minimally Invasive Pelvic Exenteration in Vaginal or Cervical Cancer Recurrence","MIPEX","Inclusion Criteria:\n\n* Diagnosis of recurrent or persistent vaginal or cervical cancer\n* Proven histological diagnosis of squamous carcinoma, adenocarcinoma or adenosquamous carcinoma\n* Isolated central pelvic recurrence\n* MRI-measured maximum tumor diameter ≤ 50 mm\n* Age \\> 18 years\n* Patients who have signed an approved informed consent form\n* Patients must be suitable for surgery\n* ECOG Performance Status of 0, 1 or 2 (Eastern Cooperative Oncology Group)\n\nExclusion Criteria:\n\n* Para-aortic lymph nodes with a short-axis diameter ≥ 15 mm on MRI scan and\u002For SUV max ≥ 2.5 on PET\u002FCT scan\n* Involvement of lateral pelvic structures (on preoperative imaging or during examination under anaesthesia)\n* Sciatic nerve involvement (at pre-operative imaging or during examination under anaesthesia)\n* Distant metastasis at PET\u002FCT scan\n* Any histological type other than squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma\n* Contraindications to surgery\n* Serious concomitant systemic disorders incompatible with surgery or minimally invasive surgery (at the discretion of the investigator)\n* Women unable to tolerate prolonged lithotomy and steep Trendelenburg positions\n* Women with secondary invasive neoplasm in the last 5 years",{"count":315,"type":20},64,[57],"The aim of this clinical trial is to assess the oncologic safety of minimally invasive pelvic exenteration in patients with recurrence or persistence of cervical or vaginal cancer with pelvic location, suitable for pelvic exenteration according to the ESGO guidelines (European Society of Gynecological Oncology). The primary aim is to assess the 3-year disease-free survival (DFS). The secondary aim is to assess the 3-year overall survival (OS), the intraoperative and post-operative complication rate, and the patient's quality of life.",[26,319],"Vaginal Cancers",[195,321,322,323,324],"vaginal cancer","minimally invasive surgery","pelvic exenteration","gynecologic oncology","2025-07-11",{"date":327,"type":33},"2025-07-17",{"date":329,"type":33},"2025-07-07",{"date":331,"type":20},"2031-03-01",{"name":333,"class":40},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":21,"phases":344,"briefSummary":345,"conditions":346,"keywords":377,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":417},"100445919","phase-1-a-beta-only-il-2-immunotherapy-study-100445919","NCT05086692","A Beta-only IL-2 ImmunoTherapY Study","A Phase 1\u002F2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors","ABILITY-1","Key Inclusion Criteria:\n\n1. Aged at least 18 years (inclusive at the time of informed consent).\n2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.\n3. Must be able and willing to provide written informed consent prior to start of any study procedures and assessments and must be willing to comply with all study procedures.\n4. Histologically or cytologically confirmed locally advanced or metastatic solid tumor (see tumor types listed under conditions)\n5. Demonstrated adequate organ function\n6. Measurable disease as per Response Evaluation Criteria in Solid Tumors, (RECIST v1.1) and documented by CT and\u002For MRI.\n7. Life expectancy of ≥ 12 weeks.\n8. Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening and within 72 hours before the first dose of study drug(s). Women must not be breastfeeding.\n9. Agree to use highly effective contraception methods. WOCBP must agree to use highly effective birth control.\n\nKey Exclusion Criteria:\n\n1. Last administration of prior antitumor therapy:\n\n   * Prior systemic anti-cancer therapy including investigational agents within 4 weeks (could consider shorter interval for kinase inhibitors or other short half-life drugs) prior to start of treatment.\n   * Prior radiotherapy within 2 weeks prior to start of treatment or has had a history of radiation pneumonitis. A 1-week washout is required for palliative radiation (\\\u003C2 weeks of radiotherapy) to non-CNS disease.\n   * Radiation therapy to the lung that is \\> 30Gy within 6 months prior to start of treatment.\n   * Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to start of treatment. Concomitant participation in an observational study must be discussed on a case-by-case basis with the MM for approval.\n2. Has known active CNS metastases and\u002For carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to start of treatment, subject to discussion with MM.\n3. Active malignancy (other than the disease under treatment in the study) within the previous 3 years except for curable cancers.\n4. Condition requiring long-term systemic treatment with either corticosteroids \\> 10 mg daily prednisone equivalent or any other form of immunosuppressive therapy within 7 days prior to start of treatment.\n5. Clinically significant active, known or suspected autoimmune disease, or diseases that can be exacerbated with immunotherapy.\n6. Severe pulmonary, cardiac or other systemic disease.\n7. Known hepatitis B or C virus infection.\n8. Females who are pregnant or lactating or planning to become pregnant during the study.\n9. Has had an allogeneic tissue\u002Fsolid organ transplant.\n10. Active infection requiring systemic therapy.\n11. Any medical, emotional or psychiatric condition that interfere with the patient's ability to adhere to the protocol\n12. Any other underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug(s) unsafe or obscure the interpretation of toxicity determination or adverse events.\n13. Known severe hypersensitivity to any component of study drug(s).\n14. Inability to comply with study and follow up procedures as judged by the Investigator.",{"count":343,"type":20},115,[79,23],"This is a Phase 1\u002F2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.",[347,348,349,350,351,352,353,113,159,354,119,355,356,357,358,114,359,360,361,362,363,364,365,366,367,368,369,370,371,84,372,373,374,375,376,26,293],"Advanced Solid Tumor","Unresectable Solid Tumor","Clear Cell Renal Cell Carcinoma","Triple Negative Breast Cancer","Non-Small Cell Lung Cancer Squamous","Non-Small Cell Lung Cancer Non-squamous","Colorectal Cancer (MSI-H)","Basal Cell Carcinoma","Merkel Cell Carcinoma","Squamous Cell Carcinoma of Head and Neck","Cutaneous Squamous Cell Carcinoma","Pleural Mesothelioma","Endometrial Carcinoma","Solid Tumor","Solid Tumor, Adult","MSI-H Solid Malignant Tumor","Cancer With A High Tumor Mutational Burden","Epithelial Ovarian Carcinoma","Primary Peritoneal Cancer","Gastroesophageal Junction (GEJ) Cancer","Acral Melanoma","Mucosal Melanoma","Cutaneous Melanoma","DMMR Solid Malignant Tumor","Fallopian Tube Cancer","MSI-H Cancer","DMMR Cancer","Pancreas Adenocarcinoma (MSI-H)","Skin Cancer","Viral Cancer",[378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,197,401,402,403,404,405,406,407],"IL-2","IL2","Interleukin-2","cancer","metastatic","ccRCC","TNBC","NSCLC","CRC","GEJ","intrahepatic","extrahepatic","MCC","SCCHN","CSCC","Gastroesophageal Junction","advanced","unresectable","MSI-H","dMMR","Microsatellite Instability-High","Mismatch Repair Deficient","PD-1","anti-PD-1","BCC","RCC","HCC","Tumor Mutation Burden High","TMB-H","PDAC","2025-07-03",{"date":410,"type":33},"2025-07-09",{"date":412,"type":33},"2021-08-27",{"date":414,"type":20},"2026-12-30",{"name":416,"class":96},"Medicenna Therapeutics, Inc.",27,{"id":419,"slug":420,"hasResults":11,"nctId":421,"briefTitle":422,"officialTitle":422,"acronym":4,"eligibilityCriteria":423,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":424,"enrollmentInfo":425,"targetDuration":4,"studyType":21,"phases":427,"briefSummary":428,"conditions":429,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":41},"100593221","phase-2-neoadjuvant-immunochemotherapy-for-locally-advanced-cervical-cancer-a-prospective-single-arm-phase-ii-clinical-trial-100593221","NCT07003620","Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial","Inclusion Criteria:\n\n* Patients with locally advanced cervical cancer (FIGO stages IB3 to IIB) and a primary tumor diameter \\>4 cm will be enrolled.\n* All patients must have histologically confirmed squamous cell carcinoma, adenosquamous carcinoma, or common adenocarcinoma.\n* ECOG performance status of 0-1.\n* no prior treatment.\n\nExclusion Criteria:\n\n* Patients with a history of other malignant tumors in the past.\n* Patients whose clinical data or treatment information is incomplete.\n* Patients with severe comorbidities or those who cannot complete follow-up.","80 Years",{"count":426,"type":20},34,[23],"This is a prospective, single-arm, Phase II clinical trial designed to evaluate the efficacy and safety of paclitaxel and carboplatin combined with PD-1\u002FPD-L1 immune checkpoint inhibitors in the treatment of locally advanced cervical cancer. Using single-cell RNA sequencing (scRNA-seq), the study aims to investigate the molecular mechanisms underlying differential treatment responses and optimize personalized therapeutic strategies.\n\nEligibility Criteria:\n\nPatients with locally advanced cervical cancer (FIGO stages IB3 to IIB) and a primary tumor diameter \\>4 cm will be enrolled. All patients must have histologically confirmed squamous cell carcinoma, adenosquamous carcinoma, or common adenocarcinoma, an ECOG performance status of 0-1, and no prior treatment.\n\nOutcome Measures:\n\n* Primary endpoint: Objective response rate (ORR), assessing tumor regression.\n* Secondary endpoints:Overall survival (OS), progression-free survival (PFS), and incidence of treatment-related adverse events (graded by CTCAE criteria).\n* Exploratory endpoint:\\*\\* Impact of treatment on the tumor microenvironment and gene expression profiles.\n\nStudy Intervention:\n\nAll patients will receive three cycles of paclitaxel and carboplatin chemotherapy combined with PD-1\u002FPD-L1 inhibitor therapy, followed by open radical hysterectomy and pelvic lymphadenectomy. Postoperative adjuvant therapy (chemotherapy, chemoradiation, or maintenance immunotherapy) will be determined based on pathological assessment. Tumor tissue samples will be collected during treatment for single-cell sequencing analysis.\n\nSample Size:\n\nThe study plans to enroll at least 34 eligible patients. Based on treatment response, patients will be categorized into high-response and low-response groups, with a minimum of 5 cases per group selected for scRNA-seq to ensure robust molecular mechanism analysis. The sample size calculation assumes a historical ORR of 65% and a target ORR of 85%.",[26],"2025-06-15",{"date":432,"type":33},"2025-06-17",{"date":434,"type":20},"2025-06-29",{"date":436,"type":20},"2028-11-30",{"name":438,"class":40},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":440,"slug":441,"hasResults":11,"nctId":442,"briefTitle":443,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":448,"phases":4,"briefSummary":449,"conditions":450,"keywords":451,"overallStatus":297,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":41},"100592929","revisiting-the-concept-of-nerve-sparing-radical-hysterectomy-100592929","NCT06999824","Revisiting the Concept of Nerve Sparing Radical Hysterectomy","Neuro-Nerve","Inclusion Criteria: (i) age ≥18 years; (ii) histologically confirmed cervical cancer; (iii) indication for type C1 (nerve-sparing) radical hysterectomy according to ESGO guidelines; and (iv) a minimum of 90 days of postoperative follow-up. Exclusion Criteria: (i) withdrawal of consent; (ii) prior abdominal and\u002For pelvic surgery; (iii) pre-existing urinary incontinence, detrusor overactivity, or detrusor underactivity; and (iv) pre-existing anorectal dysfunction Staging and architectural grade were defined according to the 2018 International Federation of Gynecology and Obstetrics (FIGO) recommendations, and histological subtypes were classified based on the World Health Organization (WHO) criteria",{"count":447,"type":20},15,"OBSERVATIONAL","Nerve-sparing radical hysterectomy aims to preserve the autonomic innervation of pelvic organs. In most studies, the preservation of the parasympathetic component of pelvic innervation is achieved by sparing the lymphovascular-neural tissue located at the base of the lateral paracervical tissue. This study explores an alternative surgical technique based on a different anatomical pathway of parasympathetic fibers, running more cranially and deeply within the pararectal space.",[26],[195,452],"radical hysterectomy","2025-05-22",{"date":455,"type":33},"2025-05-31",{"date":457,"type":20},"2025-06-01",{"date":459,"type":20},"2027-05-01",{"name":461,"class":40},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",{"id":463,"slug":464,"hasResults":11,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":469,"targetDuration":4,"studyType":21,"phases":471,"briefSummary":472,"conditions":473,"keywords":476,"overallStatus":297,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":485,"locationsCount":4},"100587503","effects-of-health-education-on-knowledge-attitude-and-screening-for-cervical-cancer-in-women-100587503","NCT06929234","Effects of Health Education on Knowledge, Attitude and Screening for Cervical Cancer in Women","Effects of Peer-Supported Health Education on Knowledge, Attitude and Screening for Cervical Cancer in Women: A Mixed Method Randomized Controlled Pilot Study","Inclusion Criteria:\n\n* Women enrolled at the Training Center,\n* Women between the ages of 30 and 65,\n* Women who are married,\n* Women who have not been screened for cervical cancer in accordance with the year interval,\n* Women who are open to communication and collaboration,\n* Women who volunteer to participate in the study will be included in the research.\n\nExclusion Criteria:\n\n* Women who have had a total hysterectomy,\n* Pregnant women,\n* Women diagnosed with cervical cancer,\n* Women who are screened on time will be excluded from the research.",{"count":470,"type":20},30,[57],"Women's knowledge, attitudes and behaviors about cancer are very important in the prevention of cervical cancer. In addition to medical interventions, psychosocial support and education programs are of great importance in the fight against cancer. Peer support helps individuals going through the same disease process to exchange information and emotional support by sharing their experiences with each other. In addition, the information obtained through peer support provides more permanent learning in individuals due to the transfer of information based on similar experiences and the creation of more trust and empathy compared to traditional education methods. Peer-supported education programs for women diagnosed with cervical cancer not only provide theoretical knowledge but also support the applicability of this knowledge in daily life. The trainings address topics such as risk factors of cervical cancer, the importance of HPV vaccination, the necessity of regular screening tests and healthy lifestyle behaviors, including attitudes towards cervical cancer prevention and cancer-related information. It is very important that this information is not limited to individual learning and that it is discussed within the group and supported by experiences through peer support, in order to increase the level of knowledge.",[474,475,26],"Peer Support","Health Education",[474,159,477,478],"Health","Education","2025-04-12",{"date":481,"type":33},"2025-04-16",{"date":483,"type":20},"2025-05-01",{"date":252,"type":20},{"name":486,"class":40},"Ordu University",{"id":488,"slug":489,"hasResults":11,"nctId":490,"briefTitle":491,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":50,"sex":51,"minAge":242,"maxAge":493,"enrollmentInfo":494,"targetDuration":4,"studyType":21,"phases":496,"briefSummary":497,"conditions":498,"keywords":500,"overallStatus":297,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":4},"100586931","remote-resilience-novel-applications-of-mhealth-in-nicaraguas-cancer-control-program-100586931","NCT06921798","Remote Resilience: Novel Applications of mHealth in Nicaragua's Cancer Control Program","Inclusion Criteria:\n\n* Between ages of 25-64\n* Owns smart phone with Android operating system\n* Lives on the Caribbean Coast of Nicaragua\n\nExclusion Criteria:\n\n* Pap test or cervical screen in the last year\n* Pregnant currently","64 Years",{"count":495,"type":20},3000,[57],"The goal of this clinical trial is to test an mHealth intervention for cervical cancer prevention in under-screened women ages 25-64 on the Caribbean Coast of Nicaragua. The mHealth intervention combines a patient-centered mobile app, a provider portal, and connectivity to the National Breast and Cervical Cancer Surveillance System (SIVIPCAN). The mHealth intervention will be combined with HPV primary screening for cervical cancer. The main questions it aims to answer are, when integrated into an HPV-based screening program:\n\nIs the mHealth intervention acceptable? Is the mHealth intervention feasible?\n\nResearchers will compare the intervention group (mHealth intervention) to the control group (standard care).\n\nParticipants will:\n\nReceive HPV-based cervical screening. Intervention group: Through the patient-centered app, participants will receive \"results ready\" notification and navigation to the clinic for follow-up.\n\nControl group: Participants will receive \"results ready\" notification and navigation to the clinic for follow-up through existing communication channels.",[499,26],"HPV Infection",[501,502,503,504,505,506],"mHealth","Nicaragua","Cervical Cancer Screening","HPV","HPV Screening","HPV Testing","2025-04-03",{"date":509,"type":33},"2025-04-10",{"date":511,"type":20},"2025-04-15",{"date":513,"type":20},"2029-05-31",{"name":515,"class":40},"University of Virginia",{"id":517,"slug":518,"hasResults":11,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":266,"enrollmentInfo":523,"targetDuration":4,"studyType":21,"phases":525,"briefSummary":526,"conditions":527,"keywords":528,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":41},"100583584","phase-2-iparomlimab-and-tuvonralimab-combined-with-paclitaxel-and-cisplatin-as-neoadjuvant-therapy-for-cc-100583584","NCT06878222","Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC","Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for Cervical Cancer: a Phase 2 Umbrella Trial","Inclusion Criteria:\n\n1. Histologically confirmed cervical squamous cell carcinoma, cervical adenocarcinoma, or cervical adenosquamous carcinoma.\n2. -Arm 1 (Locally Advanced cervical cancer): Patients with locally advanced cervical cancer classified as FIGO 2018 stages IB3, IIA2, IIB, or IIICr (lesion ≥4 cm, confirmed by MRI).\n\n   * Arm2 (cervical cancer patients desiring fertility-sparing treatment): Patients with cervical cancer classified as FIGO 2018 stages IB2, IB3 (lesion ≤6 cm), IIA1, or IIA2 (lesion ≤6 cm) who have a strong desire to preserve fertility.\n\n     3）Planned to undergo surgical treatments of cervical cancer.\n\n4\\) -Arm 1 (Locally Advanced cervical cancer): Age 18-75 years.\n\n* Arm2 (cervical cancer patients desiring fertility-sparing treatment): Age 18-45 years.\n\n  5\\) ECOG performance status score: 0-1. 6) No prior immunotherapy received by the participant. 7) Expected survival period ≥6 months. 8) Women of childbearing potential must agree to use contraception (e.g., intrauterine device, oral contraceptives, or condoms) during the study and for 6 months after the study ends. A negative serum or urine pregnancy test within 7 days before study enrollment is required, and the patient must not be breastfeeding.\n\n  9\\) Adequate organ function as defined by the protocol, with test samples collected within 7 days before the start of study treatment.\n\n  10\\) Participants voluntarily join the study, sign the informed consent form, demonstrate good compliance, and cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Histological subtypes or disease stages other than those permitted in inclusion criteria 1) and 2).\n2. Severe hypersensitivity (≥ Grade 3) to cisplatin, paclitaxel, iparomlimab and tuvonralimab, and\u002For any of their excipients.\n3. Participation in another clinical trial within 4 weeks prior to enrollment.\n4. Administration of inactivated vaccines within 30 days before the first study treatment or planned vaccination during the study period.\n5. Treatment with systemic immunostimulants, colony-stimulating factors, interferons, interleukins, or combination vaccines within 6 weeks or 5 half-lives (whichever is shorter) before the first dose.\n6. Diagnosis of immunodeficiency or chronic systemic steroid therapy (exceeding 10 mg prednisone equivalent per day) or any other form of immunosuppressive therapy within 7 days before the first dose.\n7. Active autoimmune disease requiring systemic treatment (e.g., disease-modifying drugs, corticosteroids, or immunosuppressive drugs) within the past 2 years.\n8. History of (non-infectious) pneumonitis requiring steroid treatment or current (non-infectious) pneumonitis.\n9. Active infection requiring systemic treatment.\n10. Known history of HIV infection.\n11. Known history of hepatitis B (defined as HBsAg reactivity) or active hepatitis C virus infection (defined as detectable HCV RNA \\[qualitative\\]).\n12. Known history of active tuberculosis (TB; Mycobacterium tuberculosis).\n13. Prior allogeneic tissue\u002Fsolid organ transplantation.\n14. Central nervous system metastases, such as brain metastases.\n15. Uncontrolled pleural or peritoneal effusion.\n16. Impaired mobility due to pathological fractures caused by bone metastases.\n17. Insufficient bone marrow function (without transfusion within 14 days): a) Absolute neutrophil count (ANC) \\\u003C1.5×10⁹\u002FL;b) Platelets \\\u003C100×10⁹\u002FL; c) Hemoglobin \\\u003C9 g\u002FdL.\n18. Liver abnormalities: a) ALT, AST, or ALP \\>2.5× upper limit of normal (ULN) without liver metastasis or \\>5×ULN with liver metastasis; b) Total bilirubin \\>1.5×ULN (\\>3×ULN in patients with Gilbert's syndrome); c) Decompensated cirrhosis (Child-Pugh class B or C); d) HBsAg-positive with HBV DNA ≥2000 IU\u002FmL (patients with HBsAg-positive and HBV DNA \\\u003C2000 IU\u002FmL must receive at least 2 weeks of anti-HBV therapy before the first dose); e) HCV antibody-positive with detectable HCV RNA.\n19. Kidney abnormalities: a) Serum creatinine \\>1.5×ULN or estimated creatinine clearance \\\u003C60 mL\u002Fmin using the Cockcroft-Gault formula; b) Urinalysis showing protein ≥++ and confirmed 24-hour urine protein \\>1.0 g; c) Renal failure requiring hemodialysis or peritoneal dialysis; d) History of nephrotic syndrome.\n20. Bleeding risk: a) Coagulation abnormalities: Activated partial hromboplastin time (APTT) or thrombin time (TT) \\>1.5×ULN, or international normalized ratio (INR) \\>1.5 (\\>2.5 for patients requiring anticoagulation therapy); b) History of bleeding (e.g., hemoptysis), coagulation disorders, or current use of warfarin, aspirin, low-molecular-weight heparin, or other antiplatelet agents (except for aspirin ≤100 mg\u002Fd for prophylaxis); c) Any signs or history of bleeding diathesis, regardless of severity; d) Active gastrointestinal bleeding, evidenced by hematemesis, hematochezia, or melena within the past 3 months, without resolution confirmed by endoscopy or colonoscopy; e) Any CTCAE ≥ Grade 3 bleeding or hemorrhagic event within 4 weeks before the first dose.\n21. Cardiovascular and cerebrovascular abnormalities: a) Any of the following within 12 months before the first dose: ≥ Grade 2 myocardial ischemia, yocardial infarction, arrhythmias, ≥ Grade 3 cardiac insufficiency, uncontrolled angina, coronary\u002Fperipheral artery bypass graft surgery, symptomatic congestive heart failure, cerebrovascular accident, or transient ischemic attack; b) Deep vein thrombosis or pulmonary embolism within 6 months before the first dose; c) Left ventricular ejection fraction (LVEF) \\\u003C50% assessed by Doppler ultrasound; d) Average QTc interval corrected by Fridericia's formula (QTcF) (based on at least 3 consecutive ECG readings): ≥470 ms for females; e) Uncontrolled hypertension (at least 2 measurements showing systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg).\n22. Other factors judged by the investigator as potentially affecting study results or leading to premature termination, such as alcoholism, drug abuse, other severe diseases (including mental illness) requiring concurrent treatment, significant laboratory abnormalities, or family\u002Fsocial factors that may compromise patient safety.",{"count":524,"type":20},35,[23],"Currently, the survival rate of locally advanced cervical cancer is low, posing a significant challenge in the treatment of cervical cancer. Radical chemoradiotherapy is considered the standard treatment for patients with locally advanced cervical cancer. However, 23.3% to 34.4% of patients still experience recurrence or subsequent metastasis. Radical surgery following neoadjuvant chemotherapy is an alternative to concurrent chemoradiotherapy, but it also has limitations: for approximately 9.8% to 30.6% of patients who do not respond to neoadjuvant chemotherapy, effective local treatment may be delayed. Additionally, more than 30% of patients still require adjuvant radiotherapy or chemoradiotherapy after surgery, significantly increasing the risk of complications. Therefore, there is an urgent need to explore alternative or improved treatment methods for neoadjuvant chemotherapy in locally advanced cervical cancer.\n\nAn increasing number of women are being diagnosed with cervical cancer during their childbearing years, many of whom have a desire to preserve their fertility. For selected patients with stage IB2 cervical cancer, options include abdominal radical trachelectomy or radical trachelectomy following neoadjuvant chemotherapy. However, compared to conservative surgeries such as conization or partial cervical resection, radical trachelectomy is associated with less favorable fertility rates and pregnancy outcomes, with significantly higher rates of infertility, miscarriage, and preterm birth. For patients with stage IB3 or IIA1-IIA2 cervical cancer, the current standard surgical approach is radical hysterectomy, which does not preserve fertility. Current research suggests that neoadjuvant chemotherapy can shrink tumor size, decrease lymph node and distant metastases, and reduce the need for postoperative adjuvant radiotherapy. This offers hope for young cervical cancer patients who wish to preserve fertility, as it may reduce tumor size, thereby allowing for less extensive fertility-sparing surgery, improving pregnancy outcomes, or even making fertility-sparing surgery a viable option.\n\nIn recent years, immunotherapy has gradually become a research hotspot in cancer treatment. Anti-PD-1\u002FPD-L1 monoclonal antibodies, as a type of immunotherapy drug, have demonstrated promising anti-tumor efficacy and low side effects in clinical trials. Iparomlimab and Tuvonralimab is a novel therapeutic biological product targeting both PD-1 and CTLA-4. It is composed of two engineered monoclonal antibodies (anti-PD-1 and anti-CTLA-4) expressed in a fixed ratio and has shown significant efficacy in cervical cancer patients. Therefore, given the urgent need to improve neoadjuvant therapy for locally advanced cervical cancer and fertility-preserving neoadjuvant therapy for early-stage cervical cancer patients, this study is being conducted to explore and evaluate the efficacy and safety of Iparomlimab and Tuvonralimab combined with paclitaxel and cisplatin as neoadjuvant therapy for cervical cancer. Additionally, the study aims to investigate the relationship between tumor-related biomarkers and the risk of recurrence.",[26],[195,529,530,197,531],"neoadjuvant therapy","Iparomlimab and Tuvonralimab","fertility-preserving","2025-03-30",{"date":534,"type":33},"2025-04-01",{"date":536,"type":33},"2025-03-15",{"date":538,"type":20},"2030-03-31",{"name":279,"class":40},{"id":541,"slug":542,"hasResults":11,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":546,"eligibilityCriteria":547,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":548,"targetDuration":4,"studyType":21,"phases":549,"briefSummary":551,"conditions":552,"keywords":557,"overallStatus":297,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":568,"leadSponsor":570,"locationsCount":41},"100583089","phase-4-near-infrared-fluorescence-imaging-with-indocyanine-green-to-evaluate-bowel-anastomoses-in-gynecologic-oncology-surgery-100583089","NCT06871787","Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery","Evaluation of Bowel Anastomoses During Gynecologic Oncology Surgery Using Near-Infrared Fluorescence Imaging With Indocyanine Green","INOCA","Inclusion Criteria:\n\n* Female patients aged 18 years or older.\n* Diagnosis of gynecologic cancer (ovarian, endometrial, cervical, vulvar) requiring surgical treatment.\n* Planned bowel resection and anastomosis during gynecologic oncology surgery.\n* Ability and willingness to provide informed consent.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to indocyanine green (ICG).\n* Pregnancy or breastfeeding at the time of surgery.\n* Severe liver or kidney dysfunction limiting the use of ICG.",{"count":215,"type":20},[550],"PHASE4","The goal of this study is to evaluate if indocyanine green (ICG) fluorescence imaging helps reduce complications in bowel surgery performed during gynecologic cancer operations.\n\nThe main question it aims to answer is: Does using ICG fluorescence imaging during bowel anastomosis reduce the rate of complications such as leaks, infections, and abscesses within 30 days after surgery? Participants are women aged 18 and older undergoing surgery for gynecologic cancers (such as ovarian, uterine, cervical, or vulvar cancer). During surgery, investigators will inject ICG intravenously, then use a special near-infrared camera to see how well blood flows at the anastomosis site. The investigators will then decide if the reconnection is good enough or needs adjustment.\n\nResearchers will record any complications within the first 30 days after surgery to understand if this imaging method helps reduce surgical risks.",[553,84,554,26,555,556],"Gynecologic Cancers","Endometrial Cancers","Vulvar Cancer","Anastomotic Leaks",[558,559,560,561,562,563],"Indocyanine Green","Near-Infrared Imaging","Bowel Anastomosis","Gynecologic Oncology","Anastomotic Complications","Perfusion Assessment","2025-03-11",{"date":566,"type":33},"2025-03-14",{"date":302,"type":20},{"date":569,"type":20},"2027-12-30",{"name":571,"class":40},"Istanbul University",{"id":573,"slug":574,"hasResults":11,"nctId":575,"briefTitle":576,"officialTitle":576,"acronym":4,"eligibilityCriteria":577,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":578,"targetDuration":4,"studyType":21,"phases":580,"briefSummary":581,"conditions":582,"keywords":4,"overallStatus":297,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":41},"100571746","phase-2-a-multicenter-open-label-phase-iia-clinical-study-to-evaluate-the-efficacy-and-safety-of-b1962-injection-in-the-treatment-of-advanced-malignant-solid-tumors-100571746","NCT06724263","A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors","Inclusion Criteria:\n\n* Patients must meet all of the following criteria to be eligible for enrollment in this study:\n\n  1. Voluntary participation in the study and provision of signed and dated informed consent;\n  2. Age ≥ 18 years at the time of informed consent;\n  3. Patients with histologically or cytologically confirmed advanced malignant solid tumors who have failed or failed to respond to first-line standard therapy, or cannot tolerate standard therapy, or have no standard effective treatment regimen, or refuse standard therapy; and no more than 4 lines of prior systemic anti-tumor therapy. Specific tumor species cohorts were as follows:\n\n     * Recurrent platinum-resistant epithelial ovarian cancer (including primary peritoneal and\u002For fallopian tube cancer): pathologically confirmed ovarian epithelial malignancy, fallopian tube epithelial malignancy, primary peritoneal cancer; and diagnosed platinum-resistant (duration of response to platinum-based therapy is within 6 months after the last dose of platinum-based therapy)\n\n       * Triple-negative breast cancer: pathologically confirmed unresectable locally advanced or metastatic breast cancer with negative ER, PR, and HER-2. ER, PR negativity was defined as: IHC ER \\\u003C 1%, IHC PR \\\u003C 1%. HER-2 negativity is defined as IHC HER-2 (-) or (1 +), and FISH must be performed and the result is negative for HER-2 (2 +) ③ Cervical cancer: pathologically confirmed inoperable locally advanced or metastatic cervical cancer\n\n         * Small-cell lung cancer: histologically or cytologically confirmed, inoperable, locally advanced or metastatic small-cell lung cancer\n\n           ⑤ Biliary Tract Cancer: Pathologically confirmed unresectable locally advanced or metastatic biliary tract cancer, including gallbladder cancer and intrahepatic and extrahepatic cholangiocarcinoma\n\n           ⑥ Hepatocellular carcinoma: pathologically confirmed hepatocellular carcinoma (excluding mixed hepatocellular carcinoma); Barcelona Clinic Liver Cancer (BCLC) stage C, not suitable for radical surgery and\u002For local treatment or stage B without radical progression after surgery and\u002For local treatment; Child-Pugh A liver function; for patients with esophagogastric varices, if gastroscopy or imaging, ultrasound and other examinations suggest severe (G3) varices or positive red sign, indicating high risk of venous bleeding, they are not allowed to participate in this study.\n\n           ⑦ Colorectal cancer: pathologically confirmed unresectable locally advanced or metastatic colorectal cancer\n\n           ⑧ Non-squamous non-small cell lung cancer: pathologically confirmed unresectable locally advanced or metastatic non-squamous non-small cell lung cancer that cannot contain a small cell lung cancer component.\n  4. Willingness to comply with protocol-specified visits, study treatment, laboratory tests, and other study-related procedures and requirements;\n  5. Eastern Cooperative Oncology Group (ECOG) performance score 0-1;\n  6. Expected survival time of more than 3 months;\n  7. Presence of at least one measurable lesion (non radiation therapy field) confirmed by CT or MRI that meets RECIST v1.1 criteria;\n  8. Adequate organ and bone marrow function:\n\n     Hematologic system (no transfusion, no G-CSF use, no medication for correction within 2 weeks prior to screening): absolute neutrophil count (ANC) ≥ 1.5 × 10 9\u002FL, platelets (PLT) ≥ 75 × 10 9\u002FL, hemoglobin (Hb) ≥ 90 g\u002FL； Liver function: total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN), alanine aminotransferase (ALT) ≤ 3.0 × ULN, aspartate aminotransferase (AST) ≤ 3.0 × ULN; for patients with liver metastasis: ALT ≤ 5.0 × ULN, AST ≤ 5.0 × ULN;\n\n     Renal function:\n\n     i. Creatinine ≤ 1.5 × ULN, or creatinine clearance (Ccr) ≥ 50 mL\u002Fmin (calculated according to Cockcroft-Gault formula \\*);\n\n     \\* Formula is: Ccr (ml\u002Fmin) = \\[(140-age) × weight kg × F\\]\u002F\\[serum creatinine (mg\u002Fdl) × 72\\] (F = 1 for males and 0.85 for females) ii. Urine protein \\\u003C 2 + (ie, 0, ± or 1 +) or proteinuria ≤ 1 g\u002F24 hours Note: All patients with ≥ 2 + urine protein in urinalysis must have a 24-hour urine collection and proteinuria ≤ 1 g\u002F24 hours must be confirmed Coagulation: prothrombin time (PT) ≤ 1.5 × ULN or international normalized ratio (INR) ≤ 1.5 × ULN, and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN;\n  9. For female patients:\n\n     Females of childbearing potential, who are not breastfeeding, agree to use highly effective contraception from signing the ICF and use this contraception during the study and for 3 months after the last dose; blood pregnancy results (human chorionic gonadotropin hCG) must be negative within 7 days prior to enrollment; Females of non-childbearing potential (ie, physiologically incapable of becoming pregnant), including those surgically sterilized (having undergone bilateral oophorectomy, bilateral tubal ligation, or hysterectomy), or postmenopausal for ≥ 12 months prior to Screening (amenorrhea not due to treatment);\n  10. Male patients with female partners of childbearing potential must agree to use highly effective contraception starting from signing the ICF and for the duration of the study and for 3 months after the last dose.\n\nExclusion Criteria:\n\n* Patients who meet any of the following criteria will be excluded from the study:\n\n  1. Prior use of anti-PD-1 monoclonal antibody, anti-PD-L1 monoclonal antibody, or other antineoplastic agents containing PD- (L) 1 target;\n  2. Patients who have previously used macromolecular VEGF\u002FVEGFR inhibitors such as bevacizumab, ramucirumab;\n  3. Known hypersensitivity to the study drug or any of its components, or previous severe hypersensitivity to macromolecular protein preparations\u002Fmonoclonal antibodies or bispecific antibodies;\n  4. Female patients are pregnant or lactating;\n  5. Major surgery within 4 weeks prior to the first dose of study drug, or planned major surgery within the study period; For primary or metastatic liver cancer: local treatment of liver (such as transarterial chemoembolization, transcatheter embolization, hepatic arterial infusion, radiotherapy, radioembolization or radiofrequency ablation, etc.) within 4 weeks prior to the first dose of study drug;\n  6. Adverse reactions from prior anticancer therapy that have not recovered to NCI-CTCAE v5.0 grade ≤ 1 (except alopecia and other for which the investigator considers there is no safety risk);\n  7. Patients with clinical symptoms of brain metastases, spinal cord compression, carcinomatous meningitis, or patients with other evidence of uncontrolled brain or spinal cord metastases (except for stable symptoms and imaging studies showing stable disease for at least 4 weeks before the first dose);\n  8. Patients with clinical symptoms or pleural effusion, pericardial effusion or ascites requiring repeated drainage;\n  9. Screening imaging showed tumor encasing vital blood vessels or obvious necrosis and cavity, and the investigator judged that entering the study would cause bleeding risk; according to anatomical classification of tumor location, diagnosis of central lung cancer, or tumor involving hilum with bleeding risk.\n  10. Known history of human immunodeficiency virus (HIV) infection (HIV 1\u002F2 antibody positive) or acquired immunodeficiency syndrome-related disease;\n  11. Positive hepatitis B surface antigen (HBsAg), and HBV DNA higher than the upper limit of normal value of the detection unit; or positive hepatitis C antibody (HCV-Ab) and HCV-RNA quantification \\> the upper limit of normal value of the detection unit; or known active syphilis infection;\n  12. Uncontrolled bacterial, viral, fungal infections and other pathogen infections (such as mycoplasma, parasites, etc.) requiring systemic treatment within 4 weeks prior to the first dose of study drug;\n  13. History of significant cardiovascular disease, including but not limited to: malignant arrhythmia requiring clinical intervention; or acute coronary syndrome (myocardial infarction and angina pectoris) within 6 months prior to the first dose; or congestive heart failure meeting New York Heart Association (NYHA) functional class II or higher criteria; or left ventricular ejection fraction (LVEF) \\\u003C 50%; poorly controlled hypertension with standard treatment or poor compliance with antihypertensive therapy; history of hypertensive crisis or hypertensive encephalopathy; and significant vascular disease (eg, aortic aneurysm requiring surgery);\n  14. Patients with coagulation disorders, bleeding disorders, or other conditions judged by the investigator to be at risk of bleeding, such as skin wounds, surgical sites, wound sites, severe mucosal ulcers or fractures that have not healed completely, or active gastroduodenal ulcers, gastrointestinal bleeding, intestinal obstruction, ulcerative colitis, esophagogastric varices, gastrointestinal perforation within 6 months prior to the first dose;\n  15. Pulmonary hemorrhage\u002Fhemoptysis (daily bleeding\u002Fhemoptysis volume ≥ 2.5ml) within 4 weeks prior to the first dose of study drug;\n  16. Biopsy or other minor surgery within 7 days prior to the first dose of study drug, excluding placement of vascular access devices;\n  17. Arterial or venous thrombosis, or stroke or transient ischemic attack within 6 months prior to the first dose of study drug;\n  18. Unstable anticoagulant or thrombolytic therapy within 14 days of the first dose of study drug;\n  19. Chronic treatment with aspirin (\\> 325 mg\u002Fday) or nonsteroidal anti-inflammatory drugs known to inhibit platelet function, or thienopyridines such as ticlopidine, clopidogrel, or phosphodiesterase inhibitors such as dipyridamole, cilostazol within 14 days of the first dose of study drug;\n  20. Diabetes mellitus not stably controlled by drug therapy; thyroid diseases not stably controlled by drug therapy, such as hyperthyroidism;\n  21. Current or previous idiopathic pulmonary fibrosis or idiopathic pneumonia; current acute lung disease, interstitial lung disease or pneumonia (except for local interstitial pneumonia induced by radiotherapy), pulmonary fibrosis, etc.; severe dyspnea, pulmonary insufficiency or continuous oxygen inhalation for any reason;\n  22. Active autoimmune diseases or history of autoimmune diseases requiring systemic treatment within 2 years before screening, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vasculitis or glomerulonephritis; Exceptions: hypothyroidism controlled by hormone replacement therapy alone, dermatologic conditions not requiring systemic therapy (eg, vitiligo, psoriasis), controlled celiac disease;\n  23. Systemic corticosteroid therapy (prednisone \\> 10 mg\u002Fday or equivalent of the same class) or systemic therapy with other immunosuppressive agents within 14 days prior to the first dose of study drug; Exceptions include treatment with topical, ocular, intra-articular, intranasal, or inhaled corticosteroids with minimal systemic absorption, or prophylactic short-term (≤ 7 days) use of corticosteroids (eg, allergy to contrast agents), or for the treatment of non-autoimmune conditions (eg, delayed hypersensitivity caused by contact allergens);\n  24. Received the last systemic anti-tumor therapy (biological agent therapy, etc.) within 4 weeks prior to the first dose, chemotherapy or hormone anti-tumor therapy within 2 weeks prior to the first dose, received non-specific immunomodulatory therapy (such as interleukin, interferon, thymosin, cyclophosphamide, methotrexate, thalidomide, tumor necrosis factor, etc.) within 2 weeks prior to the first dose, and received Chinese herbal medicine or Chinese patent medicine with anti-tumor indications within 1 week prior to the first dose ;\n  25. Prior organ or hematopoietic stem cell transplant;\n  26. History of other neoplasms within 5 years prior to screening, except cured cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, cervical carcinoma in situ, papillary thyroid carcinoma, who had undergone successful radical surgery;\n  27. Has received attenuated vaccines within 4 weeks prior to Screening or plans to receive attenuated vaccines during the study;\n  28. Patients who participated in a clinical study and received study drug within 4 weeks prior to the first dose;\n  29. History of alcohol or drug abuse within 12 months prior to the first dose;\n  30. Known psychiatric disorder that could affect trial compliance;\n  31. Other serious systemic diseases or laboratory abnormalities or other reasons considered unsuitable for this study by the investigator.",{"count":579,"type":20},120,[23],"This is a multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of B1962 in the treatment of ad-vanced solid tumors.\n\nThe study consists of a Screening Period, a Treatment Period, and a Follow-up Period (EOT Visit, Safety Follow-up, and Survival Follow-up).\n\nSubjects who meet the inclusion criteria and do not meet the exclusion criteria at screening will enter the appropriate study co-hort according to tumor type and receive B1962 until unacceptable toxicity, radiographic disease progression, or withdrawal of the sub-ject for other reasons, whichever comes first, for a maximum of 24 months of treatment. Enrollment will be conducted according to three stages: Stage I: It is planned to enroll 5 patients in each of 8 cohorts (tumor type) to observe the safety and efficacy; Stage II: 1 \\~ 2 cohorts are preferred to enroll 15 \\~ 20 patients to observe the ef-ficacy and safety; Stage III: 1 cohort is finally preferred to continue enrollment until a total of no more than 60 patients are observed in this cohort to observe the efficacy and safety.",[583,584,26,585,586,110,587],"Recurrent Platinum-resistant Epithelial Ovarian Cancer","Triple Negative Breast Cancer (TNBC)","Small Cell Lung Cancer","Hepatocellular Carcinoma (HCC)","Non-Squamous Non-Small Cell Lung Cancer","2024-12-04",{"date":590,"type":33},"2024-12-09",{"date":592,"type":20},"2024-12",{"date":594,"type":20},"2026-08",{"name":596,"class":96},"Tasly Biopharmaceuticals Co., Ltd.",{"id":598,"slug":599,"hasResults":11,"nctId":600,"briefTitle":601,"officialTitle":602,"acronym":603,"eligibilityCriteria":604,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":605,"targetDuration":4,"studyType":21,"phases":607,"briefSummary":608,"conditions":609,"keywords":4,"overallStatus":297,"whyStopped":4,"lastUpdateSubmitDate":616,"lastUpdatePostDateStruct":617,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":41},"100567781","phase-1-tolerance-and-effectiveness-of-c14-on-hpv-infection-100567781","NCT06672653","Tolerance and Effectiveness of C14 on HPV Infection","PREPAP Study: Tolerance and Effectiveness of the Monoterpenoid Zinc Tetra-ascorbo-camphorate (C14) on the Genital Load of Oncogenic HPV (HR-HPV) and Precancerous Cervical Lesions: Research With Direct Individual Benefit","PREPAP","Inclusion Criteria:\n\n* sexually-active women\n* aged at least 30 years old\n* who will give their informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Pregnant\n* breastfeeding and post-partum women will not be accepted in the study.\n* previous cervical surgery, medical history of any severe diseases, intake or application of other antivirals\n* known or suspected allergic or adverse response to the investigational product or its components\n* women who are unable to follow the study protocol.",{"count":606,"type":20},66,[79,23],"The zinc monoterpenoid tetra-ascorbo-camphorate possesses broad-spectrum anti-viral properties in vitro, particularly against HIV, HSV and HPV. Its C14 formulation could be a promising candidate for in vivo clinical evaluation as a potential microbicide or therapeutic drug.\n\nThe aim of this clinical trial is to determine whether C14 is effective in reducing the genital viral load of HR-HPV and in treating low-grade dysplastic lesions of the cervix. It will also determine the tolerability of C14. The main questions to be answered by the clinical trial are as follows:\n\nDoes C14 reduce the genital HR-HPV viral load in participants with persistent HR-HPV infections? What medical problems do participants experience when taking C14? Researchers will compare C14 to a placebo (a similar substance that contains no drug) to see if C14 is effective in reducing genital C14 viral load and in treating low-grade dysplastic lesions of the cervix.\n\nParticipants will\n\nreceive four monthly treatments (5ml of C14 dissolved in distilled water administered twice daily \\[morning and evening\\] for seven days via vaginal syringe during the follicular phase) of C14 or placebo for 4 months and visit the clinic once every 2 weeks for examinations and tests. They will keep a diary of their symptoms and the number of times they keep the hospital appointment.",[610,611,612,26,613,614,615],"HPV-induced Cancers","HPV Infections","HIV","Trial","C14","Monoterpenoid Zinc Tetra-ascorbo-camphorate","2024-11-01",{"date":618,"type":33},"2024-11-04",{"date":620,"type":20},"2024-11-15",{"date":622,"type":20},"2025-07-15",{"name":624,"class":96},"MGB Pharma"]